Hodgkin lymphoma

The PBS subsidises brentuximab vedotin for patients with relapsed or refractory Hodgkin lymphoma.

Treatment with brentuximab vedotin can be subsidised through the PBS under section 100 – Efficient funding of chemotherapy of the National Health Act 1953 for patients with relapsed or refractory Hodgkin lymphoma and who have failed autologous stem cell transplant (ASCT) or are ASCT naïve.

Patient eligibility

Patients must meet the relevant criteria in the restrictions and be eligible for the PBS.

The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing brentuximab vedotin.

Applications

Initial treatment – ASCT failure

All initial authority approval applications to prescribe brentuximab vedotin for the treatment of post-ASCT relapsed or refractory Hodgkin lymphoma must be made in writing: 

All applications must include a completed:

Patient must not receive more than 4 cycles of treatment under the initial treatment restriction.

Continuing treatment – ASCT failure

Applications for continuing treatment can be made by calling the PBS Complex Drugs Programs enquiry line.

Patient must not receive more than 12 cycles of treatment under the continuing treatment restriction.

Initial treatment – ASCT naïve

All initial authority approval applications to prescribe brentuximab vedotin for the treatment of ASCT naïve relapsed or refractory Hodgkin lymphoma must be made in writing: 

All applications must include a completed:

Patient must not receive more than 4 cycles of treatment under the initial treatment restriction.

Continuing treatment – ASCT naïve

Applications for continuing treatment can be made by calling the PBS Complex Drugs Programs enquiry line.

Patient must not receive more than 12 cycles of treatment under the continuing treatment restriction.

Further information

For more information contact the PBS Complex Drugs Programs enquiry line.

Page last updated: 4 April 2017

This information was printed Tuesday 27 June 2017 from humanservices.gov.au/health-professionals/enablers/hodgkin-lymphoma It may not include all of the relevant information on this topic. Please consider any relevant site notices at humanservices.gov.au/siteinformation when using this material.